New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer
By Denise Mann HealthDay Reporter MONDAY, Sept. 20, 2021 (HealthDay News) — New research offers good news for women with an aggressive HER2-positive breast cancer. A targeted therapy, trastuzumab deruxtecan (T-DXd), sold as Enhertu, triples the length of time that the cancer remains in check when compared with the current gold standard, trastuzumab emtansine (T-DM1). … Read more